Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole fMRI Study in MDD with Irritability
NCT02212613Phase 3Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Functional Magnetic Resonance Imaging BOLD Activation Score at 6 weeks. Planned start Sep 2014; status: withdrawn.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02212613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212613.